Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
This Month’s Highlights
You have accessRestricted Access

This Month’s Highlights

JASN February 2018, 29 (2) i; DOI: https://doi.org/10.1681/ASN.2017121324
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

BASIC RESEARCH

Studying Chromatin Identifies Candidate CKD Genes

Establishing causality for CKD-associated variants that are distal to protein coding regions remains challenging. Because many of these susceptibility loci overlap with DNA regulatory elements, Brandt et al. studied chromatin interactions to identify target genes that could be transcriptionally affected by these variants. In primary renal cells, their approach identified 304 target genes that may be transcriptionally dysregulated by DNA regulatory elements that colocalize with CKD-associated single nucleotide polymorphisms. This method may facilitate the identification of causal roles for many variants in CKD and other complex diseases. See Brandt et al., pages 462–476.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Collecting Duct MicroRNA Function

MicroRNAs (miRNAs) have emerged as potential therapeutic targets for genetic kidney diseases, but the physiologic role of miRNAs in postnatal renal tubules remains unknown. Using three different mouse models, Hajarnis et al. found that miRNA suppression in collecting ducts induces partial epithelial-to-mesenchymal transition, leading to progressive tubulointerstitial fibrosis and renal failure. These findings suggest that miRNAs regulate collecting duct homeostasis, which in turn has a key role in the initiation and progression of tubulointerstitial fibrosis. See Hajarnis et al., pages 518–531.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Adenosine Regulates Proton Secretion by Medullary Intercalated Cells

In several cell types, adenosine induces apical membrane accumulation of the vacuolar H+-ATPase (V-ATPase) proton pump. However, the effect of adenosine on V-ATPase in renal intercalated cells, which regulate acid-base homeostasis, is unknown. Here, Battistone et al. show that luminal adenosine signals through apical adenosine receptors in these cells, leading to stimulation of the cAMP/protein kinase A pathway and V-ATPase-dependent proton secretion. These findings reveal a novel mechanism through which intercalated cells respond to luminal purinergic agonists and may help explain the effects of adenosine-targeted therapeutics on kidney function. See Battistone et al., pages 545–556.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

CLINICAL RESEARCH

Bortezomib and Kidney Allograft Rejection

Uncontrolled studies suggest that bortezomib may be effective against late donor-specific antibody (DSA)-mediated rejection. In this issue, Eskandary et al. report results from a randomized, placebo-controlled trial undertaken to assess the effects of bortezomib in 44 DSA-positive kidney transplant recipients. Bortezomib did not significantly affect DSA levels, rejection phenotypes, graft survival, or kidney, but did associate with hematologic and gastrointestinal toxicity. These data highlight the importance of evaluating treatments for graft failure in randomized, controlled trials. See Eskandary et al., pages 591–605.

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Clinical Decision Support System for AKI

Does implementation of a clinical decision support system (CDSS) to automate the detection of AKI in the hospital setting improve outcomes? To address this question, Al-Jaghbeer et al. conducted a multicenter analysis of 528,108 patients without ESRD before admission. Use of a CDSS for AKI led to decreased hospital length of stay, mortality, and dialysis rates in patients with AKI. Outcomes for patients without AKI were not affected. Considering the incidence of AKI, these results suggest that implementation of a CDSS for AKI could save >17,000 lives and $1.2 billion annually in the United States. See Al-Jaghbeer et al., pages 654–660.

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Polyomavirus Nephropathy Classification Scheme

The effects of morphologic polyomavirus nephropathy (PVN) variants on renal allograft function are unclear. Nickeleit et al. conducted a retrospective, multicenter study of 192 patients with definitive PVN, correlating morphologic findings from index biopsies with clinical findings. On the basis of interstitial fibrosis and intrarenal polyomavirus loads, the authors defined three morphologic classes of PVN. Patients in class 1 have early PVN with favorable outcomes, and those in classes 2 and 3 have more advanced disease, with graft failure rates of up to 50% in class 3. If validated in a mixed population, this classification scheme should provide important prognostic information. See Nickeleit et al., pages 680–693

Figure6
  • Download figure
  • Open in new tab
  • Download powerpoint
  • Copyright © 2018 by the American Society of Nephrology
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 29 (2)
Journal of the American Society of Nephrology
Vol. 29, Issue 2
February 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
This Month’s Highlights
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
This Month’s Highlights
JASN Feb 2018, 29 (2) i; DOI: 10.1681/ASN.2017121324

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
This Month’s Highlights
JASN Feb 2018, 29 (2) i; DOI: 10.1681/ASN.2017121324
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • BASIC RESEARCH
    • CLINICAL RESEARCH
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • This Month's Highlights
  • This Month’s Highlights
  • This Month's Highlights
Show more This Month’s Highlights

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire